GLP-1S

GLP-1S corresponds to semaglutide, an acylated analog of human glucagon-like peptide-1 (GLP-1). A C-18 fatty-diacid moiety attached through a linker confers albumin binding and an extended plasma half-life relative to native GLP-1. It is studied as a long-acting, selective GLP-1 receptor agonist reference compound.

The research literature attributes its activity to selective agonism at the GLP-1 receptor, a class-B G-protein-coupled receptor. In pancreatic beta-cell models, receptor activation is associated with glucose-dependent cyclic-AMP signaling and insulin secretion; in preclinical models the literature also describes suppression of glucagon release, slowed gastric emptying, and reduced food intake mediated through hypothalamic and brainstem circuits.

Contexts in which this compound appears in the in-vitro and preclinical research literature:

• Beta-cell culture: glucose-dependent insulinotropic signaling and cAMP/PKA endpoints.
• Rodent models of diet-induced obesity and impaired glucose tolerance.
• Central-circuit studies of appetite and energy-balance signaling.
• Comparative pharmacology against native GLP-1 and shorter-acting analogs (half-life, receptor kinetics).

Supplied lyophilized for laboratory reconstitution. Reconstitute with bacteriostatic water to the concentration your protocol requires (for example, 2 mL into a 10 mg vial gives 5 mg/mL). Add diluent slowly down the vial wall and swirl, do not shake, and aliquot after reconstitution to limit freeze–thaw exposure.

Store sealed lyophilized vials at −20 °C, protected from light. Refrigerate reconstituted material at 2–8 °C and protect it from repeated freeze–thaw.

Independent and in-house certificates published for this compound. Each reports identity and HPLC purity for the tested lot.